Goldman Sachs initiated coverage of BioAge Labs (BIOA) with a Not Rated. The firm models for peak azelaprag sales of $8.5B in 2036 via peak penetration of 15% into the incretin-treated market.
Goldman Sachs analyst Rajan Sharma introduced a Buy rating and $13.50 price target for Immatics (IMTX) after previously being Not Rated on the early-stage biotech company. The firm is positive on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback